<DOC>
	<DOCNO>NCT02136797</DOCNO>
	<brief_summary>The purpose study see well transfusion T-cells work treat CMV . Tcells type white blood cell help protect body infection . A transfusion process blood one person transfer blood another . In case , T-cells make blood donor immune CMV . The T-cells grown teach attack CMV virus lab .</brief_summary>
	<brief_title>Trial Third Party Donor Derived CMVpp65 Specific T-cells The Treatment CMV Infection Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Viremia</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<criteria>Each patient must satisfy least one follow criterion : 1 . The patient must clinically document condition associate CMV ( e.g . interstitial pneumonia , hepatitis , retinitis , colitis ) Or 2 . The patient must microbiological evidence CMV viremia tissue invasion attest viral culture , detection level CMV DNA blood body fluids consistent CMV infection . Patient must also satisfy least one follow criterion : 1 . The patient 's CMV infection clinically progress CMV viremia persistent increase ( evidence quantitation CMV DNA blood ) despite two week induction therapy antiviral drug . Or 2 . The patient develop CMV viremia attest viral culture , detection level CMV DNA blood body fluid receive prophylactic dos antiviral drug prevent CMV infection post transplant . Or 3 . The patient unable sustain treatment antiviral drug due drug associate toxicity ( e.g . myelosuppression [ ANC &lt; 1000μl/ml without GCSF support ] nephrotoxicity [ correct creatinine clearance ≤ 60 ml/min/1.73 m^2 serum creatinine &gt; 2 mg/dl ] ) CMV infection life threatening , may involve multiple organ system lung , liver , gastrointestinal tract , hematopoietic central nervous system . Antiviral drug use treatment may also compromise renal hematopoietic function . Therefore , dysfunction organ affect eligibility protocol . Patients must meet follow clinical criterion receive CMVpp65CTL infusion 1 . Stable blood pressure circulation , require pressor support 2 . Evidence adequate cardiac function demonstrate EKG and/or echocardiography . 3 . A life expectancy least 3 week , even require artificial ventilation . 4 . There age restriction Patient must also satisfy least one follow criterion : 1 . The patient 's HCT donor previously infect sensitize CMV ( e.g . cord blood transplant marrow PBSC transplant seronegative donor ) . 2 . The patient 's HCT donor , seropositive , either available willing provide leukocytes generation CMVspecific Tcells . 3 . There CMVpp65specific Tcells available appropriate dos MSKCC Adoptive Immune Tcell Therapy Bank match patient 1 HLA allele exhibit CMVpp65specific cytotoxic activity restrict HLA allele share patient Patients require high dos glucocorticosteroids ( ≥ 0.3 mg/kg prednisone equivalent ) Patients moribund Patients condition related CMV infection ( e.g . uncontrolled bacterial sepsis invasive fungal infection ) also lifethreatening would preclude evaluation effect Tcell infusion . Patients pregnant</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>CMVpp65 Specific T-cells</keyword>
	<keyword>Allogeneic Hematopoietic Stem Cell Transplantation</keyword>
	<keyword>14-070</keyword>
</DOC>